Glaxo 14

“Paxil maker releases youth studies”
GlaxoSmithKline is target of suit alleging it withheld data drug is harmful to children.

Bloomberg News - June 15, 2004

GlaxoSmithKline Plc, accused in a U.S. lawsuit of withholding findings about the antidepressant Paxil's effect on children, posted on its Web site studies it sponsored on the medication's use in youngsters. The documents include nine studies evaluating Paxil in childhood depression, obsessive compulsive disorder and social anxiety disorder, as well as a bibliography of 30 titles of company-sponsored studies that were published in medical journals or presented at scientific meetings. Also included is a letter Glaxo sends to doctors who request the latest information on the use of Paxil in young people.

New York Attorney General Eliot Spitzer on June 2 filed a lawsuit against Brentford, England-based Glaxo alleging it fraudulently withheld data from doctors that showed Paxil may be harmful to children and teenagers. Glaxo, Europe's biggest drugmaker, denies the allegations.

"The regulators have all this information. They've also been publicly communicated," said Glaxo spokesman David Mawdsley. "What we're doing is to be more transparent by putting the information on the Web site." In a statement, Spitzer called Glaxo's action "a positive first step toward changing a dangerous industry practice."

"While today's development by (Glaxo) does not resolve all of the issues in our litigation, it does represent movement in the right direction," Spitzer said.

GSK Studies:
http://www.gsk.com/media/paroxetine.htm